Tumour necrosis factor-α in nasal allergy

Tumour necrosis factor-α in nasal allergy

Tumour necrosis factor-alpha (TNF-alpha) was measured by enzyme-linked immunosorbent assay and eosinophil cationic protein (ECP) by radio-immunoassay to evaluate TNF-alpha in nasal allergy. There was no significant difference either between the mean concentrations of TNF-alpha in nasal secretions from the patients with perennial nasal allergy and those of normal subjects, or between the TNF-alp...

Anti-Tumour Necrosis Factor-α Therapy in Crohn’s Disease

Crohn’s disease is a chronic, relapsing, inflammatory disease of the gastro-intestinal tract. Manifestations of the disease may be severe, and lead to long-term therapy with a variety of medications and/or surgery. There are two main classifications of the disease, including the relapsing-remitting chronic active variety, and the penetrating or fistulising variety. Tumour necrosis factor-alpha ...

Circulating tumour necrosis factor α and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis

Objective: To examine the relation between the serum levels of tumour necrosis factor α (TNFα), soluble tumour necrosis factor receptors (sTNF-R), and the histological pattern of rheumatoid synovitis. Methods: An enzyme linked immunosorbent assay (ELISA) was used to measure TNFα, p55 sTNF-R, and p75 sTNF-R concentrations in the serum of 43 patients with rheumatoid arthritis (RA) and 34 patients...

Anti-Tumour Necrosis Factor-α Induced Systemic Lupus Erythematosus

Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.

Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes between the two diseases. A total of 1165 patients were screened for TB and treated with TNF-α antagonists from July 2004 to July 2013 for the following conditions: inflammatory bowel disease (n = 422), rheumatoid arthriti...